{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:58:12Z","timestamp":1783403892860,"version":"3.54.6"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The objective of this study was to compare transperineal (TP) versus transrectal (TR) magnetic resonance imaging (MRI) and transrectal ultrasound (TRUS) fusion prostate biopsy (PBx). Consecutive men who underwent prostate MRI followed by a systematic biopsy. Additional target biopsies were performed from Prostate Imaging Reporting &amp; Data System (PIRADS) 3\u20135 lesions. Men who underwent TP PBx were matched 1:2 with a synchronous cohort undergoing TR PBx by PSA, Prostate volume (PV) and PIRADS score. Endpoint of the study was the detection of clinically significant prostate cancer (CSPCa; Grade Group\u2009\u2265\u20092). Univariate and multivariable analyses were performed. Results were considered statistically significant if p\u2009&lt;\u20090.05. Overall, 504 patients met the inclusion criteria. A total of 168 TP PBx were pair-matched to 336 TR PBx patients. Baseline demographics and imaging characteristics were similar between the groups. Per patient, the CSPCa detection was 2.1% vs 6.3% (p\u2009=\u20090.4) for PIRADS 1\u20132, and 59% vs 60% (p\u2009=\u20090.9) for PIRADS 3\u20135, on TP vs TR PBx, respectively. Per lesion, the CSPCa detection for PIRADS 3 (21% vs 16%; p\u2009=\u20090.4), PIRADS 4 (51% vs 44%; p\u2009=\u20090.8) and PIRADS 5 (76% vs 84%; p\u2009=\u20090.3) was similar for TP vs TR PBx, respectively. However, the TP PBx showed a longer maximum cancer core length (11 vs 9\u00a0mm; p\u2009=\u20090.02) and higher cancer core involvement (83% vs 65%; p\u2009&lt;\u20090.001) than TR PBx. Independent predictors for CSPCa detection were age, PSA, PV, abnormal digital rectal examination findings, and PIRADS 3\u20135. Our study demonstrated transperineal MRI\/TRUS fusion PBx provides similar CSPCa detection, with larger prostate cancer core length and percent of core involvement, than transrectal PBx.<\/jats:p>","DOI":"10.1038\/s41598-023-40371-7","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T11:02:10Z","timestamp":1692356530000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Transperineal vs transrectal magnetic resonance and ultrasound image fusion prostate biopsy: a pair-matched comparison"],"prefix":"10.1038","volume":"13","author":[{"given":"Masatomo","family":"Kaneko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis G.","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Sarah L.","family":"Lenon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sij","family":"Hemal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aref S.","family":"Sayegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donya S.","family":"Jadvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo Storino","family":"Ramacciotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divyangi","family":"Paralkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni E.","family":"Cacciamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir H.","family":"Lebastchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodour","family":"Salhia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Aron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Hopstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Duddalwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne L.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inderbir S.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre Luis","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,18]]},"reference":[{"key":"40371_CR1","unstructured":"Mottet, N. et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Eur. Assoc. Urol. 1\u2013234 https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2023_2023-03-27-131655_pdvy.pdf (2023)."},{"key":"40371_CR2","unstructured":"Moses, K. A. et al. Prostate cancer early detection version 1.2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate_detection.pdf (2023)."},{"key":"40371_CR3","unstructured":"NICE. NICE guideline Prostate cancer: Diagnosis and management. https:\/\/www.nice.org.uk\/guidance\/ng131\/resources\/prostate-cancer-diagnosis-and-management-pdf-66141714312133 (2019)."},{"key":"40371_CR4","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/JU.0000000000000617","volume":"203","author":"MA Bjurlin","year":"2020","unstructured":"Bjurlin, M. A. et al. Update of the standard operating procedure on the use of multiparametric magnetic resonance imaging for the diagnosis, staging and management of prostate cancer. J. Urol. 203, 706\u2013712 (2020).","journal-title":"J. Urol."},{"key":"40371_CR5","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.euo.2020.12.012","volume":"4","author":"BP Rai","year":"2021","unstructured":"Rai, B. P. et al. Magnetic resonance imaging\/ultrasound fusion-guided transperineal versus magnetic resonance imaging\/ultrasound fusion-guided transrectal prostate biopsy-A systematic review. Eur. Urol. Oncol. 4, 904\u2013913 (2021).","journal-title":"Eur. Urol. Oncol."},{"key":"40371_CR6","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1111\/bju.15272","volume":"127","author":"A Fujihara","year":"2021","unstructured":"Fujihara, A. et al. Multiparametric magnetic resonance imaging facilitates reclassification during active surveillance for prostate cancer. BJU Int. 127, 712\u2013721 (2021).","journal-title":"BJU Int."},{"key":"40371_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","volume":"69","author":"JC Weinreb","year":"2016","unstructured":"Weinreb, J. C. et al. PI-RADS prostate imaging\u2014Reporting and data system: 2015, version 2. Eur. Urol. 69, 16\u201340 (2016).","journal-title":"Eur. Urol."},{"key":"40371_CR8","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey, B. et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur. Urol. 76, 340\u2013351 (2019).","journal-title":"Eur. Urol."},{"key":"40371_CR9","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.1007\/s00330-020-06929-z","volume":"30","author":"M de Rooij","year":"2020","unstructured":"de Rooij, M. et al. ESUR\/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: Quality requirements for image acquisition, interpretation and radiologists\u2019 training. Eur. Radiol. 30, 5404\u20135416 (2020).","journal-title":"Eur. Radiol."},{"key":"40371_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/JU.0000000000001766","volume":"206","author":"A Tafuri","year":"2021","unstructured":"Tafuri, A. et al. Systematic biopsy of the prostate can be omitted in men with PI-RADS\u2122 5 and prostate specific antigen density greater than 15%. J. Urol. 206, 289\u2013297 (2021).","journal-title":"J. Urol."},{"key":"40371_CR11","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00345-019-02835-2","volume":"38","author":"A Tafuri","year":"2020","unstructured":"Tafuri, A. et al. One-stop MRI and MRI\/transrectal ultrasound fusion-guided biopsy: An expedited pathway for prostate cancer diagnosis. World J. Urol. 38, 949\u2013956 (2020).","journal-title":"World J. Urol."},{"key":"40371_CR12","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.3390\/cancers13061449","volume":"13","author":"D Sugano","year":"2021","unstructured":"Sugano, D. et al. Comparative effectiveness of techniques in targeted prostate biopsy. Cancers (Basel) 13, 1449 (2021).","journal-title":"Cancers (Basel)"},{"key":"40371_CR13","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1097\/JU.0000000000001234","volume":"204","author":"G Marra","year":"2020","unstructured":"Marra, G. et al. Pain in men undergoing transperineal free-hand multiparametric magnetic resonance imaging fusion targeted biopsies under local anesthesia: Outcomes and predictors from a multicenter study of 1008 patients. J. Urol. 204, 1209\u20131215 (2020).","journal-title":"J. Urol."},{"key":"40371_CR14","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/bju.15985","volume":"131","author":"M Kaneko","year":"2023","unstructured":"Kaneko, M. et al. Transperineal magnetic resonance imaging\/transrectal ultrasonography fusion prostate biopsy under local anaesthesia: The \u2018double-freehand\u2019 technique. BJU Int. 131, 770\u2013774. https:\/\/doi.org\/10.1111\/bju.15985 (2023).","journal-title":"BJU Int."},{"key":"40371_CR15","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein, J. I. et al. The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma definition of grading patterns and proposal for a new grading system. Am. J. Surg. Pathol. 40, 244\u2013252 (2016).","journal-title":"Am. J. Surg. Pathol."},{"key":"40371_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.juro.2017.01.103","volume":"198","author":"MA Liss","year":"2017","unstructured":"Liss, M. A. et al. An update of the american urological association white paper on the prevention and treatment of the more common complications related to prostate biopsy. J. Urol. 198, 329\u2013334 (2017).","journal-title":"J. Urol."},{"key":"40371_CR17","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1097\/JU.0000000000000156","volume":"201","author":"V Stefanova","year":"2019","unstructured":"Stefanova, V. et al. Transperineal prostate biopsies using local anesthesia: Experience with 1287 patients. Prostate cancer detection rate complications and patient tolerability. J. Urol. 201, 1121\u20131126 (2019).","journal-title":"J. Urol."},{"key":"40371_CR18","unstructured":"NIH Policy on the inclusion of women and minorities as subjects in clinical research. https:\/\/grants.nih.gov\/policy\/inclusion\/women-and-minorities\/guidelines.htm (2001)."},{"key":"40371_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo, D., Demartines, N. & Clavien, P. A. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann. Surg. 240, 205\u2013213 (2004).","journal-title":"Ann. Surg."},{"key":"40371_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12957-019-1573-0","volume":"17","author":"J Xiang","year":"2019","unstructured":"Xiang, J. et al. Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: A systematic review and meta-analysis. World J. Surg. Oncol. 17, 1\u201311 (2019).","journal-title":"World J. Surg. Oncol."},{"key":"40371_CR21","first-page":"650","volume":"38","author":"LM Loy","year":"2020","unstructured":"Loy, L. M. et al. A systematic review and meta-analysis of magnetic resonance imaging and ultrasound guided fusion biopsy of prostate for cancer detection\u2014Comparing transrectal with transperineal approaches. Urol. Oncol. Semin. Orig. Investig. 38, 650\u2013660 (2020).","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"40371_CR22","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1097\/JU.0000000000002802","volume":"208","author":"F Zattoni","year":"2022","unstructured":"Zattoni, F. et al. The detection of prostate cancer with magnetic resonance imaging-targeted prostate biopsies is superior with the transperineal vs the transrectal approach. A European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-Ins. J. Urol. 208, 830\u2013837 (2022).","journal-title":"J. Urol."},{"key":"40371_CR23","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41391-020-0205-7","volume":"23","author":"Y Ber","year":"2020","unstructured":"Ber, Y. et al. A noninferiority within-person study comparing the accuracy of transperineal to transrectal MRI\u2013US fusion biopsy for prostate-cancer detection. Prostate Cancer Prostatic Dis. 23, 449\u2013456 (2020).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"40371_CR24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/pros.24288","volume":"82","author":"MY Koparal","year":"2022","unstructured":"Koparal, M. Y. et al. Comparison of transperineal and transrectal targeted prostate biopsy using Mahalanobis distance matching within propensity score caliper method: A multicenter study of Turkish Urooncology Association. Prostate 82, 425\u2013432 (2022).","journal-title":"Prostate"},{"key":"40371_CR25","doi-asserted-by":"publisher","first-page":"037502","DOI":"10.1117\/1.JMI.2.3.037502","volume":"2","author":"KD Rojas","year":"2015","unstructured":"Rojas, K. D. et al. Methodology to study the three-dimensional spatial distribution of prostate cancer and their dependence on clinical parameters. J. Med. Imaging 2, 037502 (2015).","journal-title":"J. Med. Imaging"},{"key":"40371_CR26","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.euo.2021.06.001","volume":"5","author":"AS Bajeot","year":"2022","unstructured":"Bajeot, A. S. et al. Managing discordant findings between multiparametric magnetic resonance imaging and transrectal magnetic resonance imaging-directed prostate biopsy-the key role of magnetic resonance imaging-directed transperineal biopsy. Eur. Urol. Oncol. 5, 296\u2013303 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"40371_CR27","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed, H. U. et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study. Lancet 389, 815\u2013822 (2017).","journal-title":"Lancet"},{"key":"40371_CR28","unstructured":"Shaeffer, E. M. et al. NCCN guideline prostate cancer version 1. NCCN https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf (2023)."},{"key":"40371_CR29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.juro.2018.03.078","volume":"200","author":"P Jiang","year":"2018","unstructured":"Jiang, P., Liss, M. A. & Szabo, R. J. Targeted antimicrobial prophylaxis does not always prevent sepsis after transrectal prostate biopsy. J. Urol. 200, 361\u2013368 (2018).","journal-title":"J. Urol."},{"key":"40371_CR30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.euros.2022.01.001","volume":"37","author":"SP Basourakos","year":"2022","unstructured":"Basourakos, S. P. et al. Role of prophylactic antibiotics in transperineal prostate biopsy: A systematic review and meta-analysis. Eur. Urol. Open Sci. 37, 53\u201363 (2022).","journal-title":"Eur. Urol. Open Sci."},{"key":"40371_CR31","first-page":"1","volume":"3099","author":"M Jacewicz","year":"2022","unstructured":"Jacewicz, M. et al. Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): A randomised, open-label, non-inferiority trial. Lancet Infect. Dis. 3099, 1\u20137 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"40371_CR32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/pan\/mpl013","volume":"15","author":"DE Ho","year":"2007","unstructured":"Ho, D. E., Imai, K., King, G. & Stuart, E. A. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Polit. Anal. 15, 199\u2013236 (2007).","journal-title":"Polit. Anal."},{"key":"40371_CR33","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.urology.2020.07.072","volume":"146","author":"JS Winoker","year":"2020","unstructured":"Winoker, J. S. et al. Transperineal versus transrectal targeted biopsy with use of electromagnetically-tracked MR\/US fusion guidance platform for the detection of clinically significant prostate cancer. Urology 146, 278\u2013286 (2020).","journal-title":"Urology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-40371-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-40371-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-40371-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T02:14:43Z","timestamp":1700532883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-40371-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["40371"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-40371-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,18]]},"assertion":[{"value":"14 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Andre Luis Abreu is consultant for Koelis and Quibim and a proctor for EDAP. Other authors do not have any competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13457"}}